Blood-based biomarkers in patients with platinum-sensitive and resistant ovarian cancer treated with olaparib and cediranib: results from the UM9825 trial
Andrew B. Nixon(Duke University), Angeles Alvarez Secord(Duke University), Kouros Owzar(Duke University), Stéphanie Gaillard(Sidney Kimmel Cancer Center), Yingmiao Liu(Duke Medical Center), Andrea Wahner Hendrickson(Mayo Clinic in Arizona), Robert M. Wenham(Moffitt Cancer Center), Mihaela Cristea(City Of Hope National Medical Center), Herbert I. Hurwitz(Duke Medical Center), Alexander Olawaiye(Magee-Womens Hospital), Niya Xiong(Dana-Farber Cancer Institute), Joyce F. Liu(Duke University), Mark D. Starr(Duke Medical Center), Jing Lyu(University College Dublin), S. Percy Ivy(National Cancer Institute), Nancy Chan(Unknown), Elizabeth M. Swisher(University of Washington), James L. Abbruzzese(Duke University), Richard T. Penson(Massachusetts General Hospital), Deborah K. Armstrong(Johns Hopkins University), David E. Cohn(The Ohio State University), Jungmin Lee(National Cancer Institute), Koji Matsuo(University of Southern California), John C. Brady(Duke Medical Center), Elise C. Kohn(National Cancer Institute)
Cited by 1
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k